Integrase inhibitors to treat HIV/AIDS

Nature Reviews Drug Discovery

Volumn 4, Issue 3, 2005, Pages 236-248

  Pommier, Yves ^a   Johnson, Allison A ^a   Marchand, Christophe ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; ANTIVIRUS AGENT; CAFFEIC ACID PHENETHYL ESTER; CICHORIC ACID; COUMARIN DERIVATIVE; DELAVIRDINE; DIDANOSINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; FZ 41; HYPERICIN; INDOLICIDIN; INTEGRASE; INTEGRASE INHIBITOR; L 708906; L 870812; LEXITROPSIN; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; NAPHTHYRIDINE DERIVATIVE; NEVIRAPINE; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; ROLITETRACYCLINE; STAVUDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; V 165; ZALCITABINE; ZIDOVUDINE; ZINTEVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME STRUCTURE; FOOD AND DRUG ADMINISTRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN NUCLEIC ACID INTERACTION; REVIEW; RHESUS MONKEY; VIRUS NUCLEOCAPSID; VIRUS REPLICATION;

AFRICA SOUTH OF THE SAHARA; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG APPROVAL; HIV; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; MUTATION; STRUCTURE-ACTIVITY RELATIONSHIP; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VIRUS REPLICATION;

EID: 14944374558     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1660     Document Type: Review

References (99)

1. Gottlieb, M. S. et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med. 305 1425-1431 (1981).
2. Masur, H. et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: inital manifestation of cellular immune dysfunction. N. Engl. J. Med. 305, 1431-1438 (1981).
3. Siegal, F. P. et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N. Engl. J. Med. 305, 1439-1444 (1981).
4. Jaffe, H. Public health. Whatever happened to the US AIDS epidemic? Science 305, 1243-1244 (2004).
5. Richman, D. D. HIV chemotherapy. Nature 410, 995-1001 (2001).
6. Cohen, J. Therapies. Confronting the limits of success. Science 296, 2320-2324 (2002).
7. Hazuda, D. J. et al. Integrase Inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305, 528-532 (2004).
8. Werber, Y. HIV drug market. Nature Rev. Drug Discov. 2, 513-514 (2003).
9. Fesen, M. R., Kohn, K. W., Leteurtre, F. & Pommier, Y. Inhibitors of human immunodeficiency virus integrase. Proc. Natl Acad. Sci. USA 90, 2399-2403 (1993).
10. Cushman, M. & Sherman, P. Inhibition of HIV-1 integration protein by aurintricarboxylic acid monomers, monomer analogs, and polymer fractions. Biochem. Biophys. Res. Commun. 185, 85-90 (1992).
11. Carteau, S., Mouscadet, J.-F., Goulaouic, H., Subra, F. & Auclair, C. Inhibitory Effect of the polyanionic drug suramin on the in vitro HIV DNA integration reaction. Arch. Biochem. Biophys. 305, 606-610 (1993).
12. Tsurutani, N. et al. Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells. J. Virol. 74, 4795-4806 (2000).
13. Zhu, K., Dobard, C. & Chow, S. A. Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase. J. Virol. 78, 5045-5055 (2004).
14. Brown, P. O. in Retroviruses (eds. Coffin, J. M., Hughes, S. H. & Varmus, H. E.) 161-203 (Cold Spring Harbor Press, Cold Spring Harbor, 1998).
15. Turlure, F., Devroe, E., Silver, P. A. & Engelman, A. Human cell proteins and human immunodeficiency virus DNA integration. Front Biosci. 9, 3187-3208 (2004).
16. Kalpana, G. V. & Goff, S. P. Protein-protein interactions of HIV-1 IN: INI-1 (IN Interactor-1), a novel human gene with sequence similarity to yeast transcription factor SNF5. J. Cell. Biochem. 18B, 27 (1994).
17. Cherepanov, P. et al. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J. Biol. Chem. 278, 372-381 (2002).
18. Violot, S. et al. The human polycomb group EED protein interacts with the integrase of human immunodeficiency virus type 1. J. Virol. 77, 12507-12522 (2003).
19. Parissi, V. et al. Functional interactions of human immunodeficiency virus type 1 integrase with human and yeast HSP60. J. Virol. 75, 11344-11353 (2001).
20. Turelli, P. et al. Cytoplasmic recruitment of ini1 and pml on incoming HIV preintegration complexes. Interference with early steps of viral replication. Mol. Cell 7, 1245-1254 (2001).
21. Hindmarsh, P. et al. HMG protein family members stimulate human immunodeficiency virus type 1 and avian sarcoma virus concerted DNA integration in vitro. J. Virol. 73, 2994-3003 (1999).
22. Farnet, C. & Bushman, F. D. HIV-1 cDNA integration: requirement of HMG I (Y) protein for function of preintegration complexes in vitro. Cell 88, 483-492 (1997).
23. Bukrinsky, M. I. et al. Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc. Natl. Acad. Sci. USA 89, 6680-6584 (1992).
24. Chow, S. A., Vincent, K. A., Ellison, V. & Brown, P. O. Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science 255, 723-726 (1992).
25. Yoder, K. E. & Bushman, F. D. Repair of gaps in retroviral DNA integration intermediates. J. Virol. 74, 11191-11200 (2000).
26. Daniel, R. et al. Evidence that stable retroviral transduction and cell survival following DNA integration depend on components of the nonhomologous end joining repair pathway. J. Virol. 78, 8573-8581 (2004).
27. Carteau, S., Hoffmann, C. & Bushman, F. Chromosome structure and human immunodeficiency virus type 1 cDNA integration: centromeric alphoid repeats are a disfavored target. J. Virol. 72, 4005-4014 (1998).
28. Schroder, A. R. et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521-529 (2002).
29. Bor, Y. C., Miller, M. D., Bushman, F. D. & Orgel, L. E. Target-sequence preferences of HIV-1 integration complexes in vitro. Virology 222, 283-288 (1996).
30. Pryciak, P. M. & Varmus, H. E. Nucleosomes, DNA-binding proteins, and DNA sequence modulate retroviral integration target site selection. Cell 69, 769-780 (1992).
31. Wu, X., Li, Y., Crise, B. & Burgess, S. M. Transcription start regions in the human genome are favored targets for MLV integration. Science 300, 1740-1751 (2003).
32. Chiu, T. K. & Davies, D. R. Structure and function of HIV-1 integrase. Curr. Top. Med. Chem. 4, 965-77 (2004).
33. Chen, J. C. et al. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc. Natl Acad. Sci. USA 97, 8233-8238 (2000).
34. Wang, J. Y., Ling, H., Yang, W. & Craigie, R. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J. 20, 7333-7343 (2001).
35. Yang, W. & Steitz, T. A. Recombining the structures of HIV integrase, RuvC and RNase H. Structure 3, 131-134 (1995).
36. Song, J. J., Smith, S. K., Hannon, G. J. & Joshua-Tor, L. Crystal structure of Argonaute and its implications for RISC slicer activity. Science 305, 1434-1437 (2004).
37. Rice, P. A. & Baker, T. A. Comparative architecture of transposase and integrase complexes. Nature Struct. Biol. 8, 302-307 (2001).
38. Bujacz, G. et al. Binding of different divalent cations to the active site of avian sarcoma virus integrase and their effects on enzymatic activity. J. Biol. Chem. 272, 18161-18168 (1997).
39. Beese, L. S. & Steitz, T. A. Structural basis for the 3′-5′ exonuclease activity of Escherichia coli DNA polymerase I: a two metal ion mechanism. EMBO J. 10, 25-33 (1991).
40. Grobler, J. A. et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl Acad. Sci. USA 99, 6661-6666 (2002).
41. Marchand, C. et al. Metal-dependent inhibition of HIV-1 integrase by β-diketo acids and resistance of the soluble double-mutant (F185K/C280S). Mol. Pharmacol. 64, 600-609 (2003).
42. Chow, S. A. & Brown, P. O. Juxtaposition of two viral DNA ends in a bimolecular disintegration reaction mediated by multimers of human immunodeficiency virus type 1 or murine leukemia virus integrase. J. Virol. 68, 7869-7878 (1994).
43. Engelman, A., Bushman, F. D. & Craigie, R. Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO J. 12, 3269-3275(1993).
44. Engelman, A. & Craigie, R. Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase functon in vitro. J. Virol. 66, 6361-6369 (1992).
45. Melek, M. et al. Effect of HIV integrase inhibitors on the RAG1/2 recombinase. Proc. Natl Acad. Sci USA 99, 134-137 (2002).
46. Shaw-Reid, C. A. et al. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J. Biol. Chem. 278, 2777-2780 (2003).
47. Sherman, P. A. & Fyfe, J. A. Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity. Proc. Natl Acad. Sci. USA 87, 5119-5123 (1990).
48. Craigie, R., Mizuuchi, K., Bushman, F. D. & Engelman, A. A rapid in vitro assay for HIV DNA integration. Nucleic Acids Res. 19, 2729-2734 (1991).
49. Hazuda, D. J., Hastings, J. C., Wolfe, A. L. & Emini, E. A. A novel assay for the DNA strand-transfer reaction of HIV-1 integrase. Nucleic Acids Res. 22, 1121-1122 (1994).
50. Vink, C., Banks, M., Bethell, R. & Plasterk, R. H. A. A high-throughput, non-radioactive microtiter plate assay for activity of the human immnodeficiency virus integrase protein. Nucleic Acids Res. 22, 2176-2177 (1994).
51. Johnson, A. A., Marchand, C. & Pommier, Y. HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. Curr. Top. Med. Chem. 4, 1059-1077 (2004).
52. Dayam, R. & Neamati, N. Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update. Curr Pharm Des 9, 1789-1802 (2003).
53. Neamati, N. Patented small molecules inhibitors of HIV-1 integrase: a 10-year saga. Expert Opin. Ther. Patents 12, 709-724 (2002).
54. Witvrouw, M. et al. Novel inhibitors of HIV-1 integration. Curr. Drug. Metab. 5, 291-304 (2004).
55. Young, S. D. Inhibition of HIV-1 integrase by small molecules: the potential for a new class of AIDS chemotherapeutics. Curr. Opin. Drug Discov. Devel. 4, 402-410 (2001).
56. Hazuda, D. J. et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287, 646-650 (2000).
57. Pannecouque, C. et al. New class of HIV integrase inhibitors that block viral replication in cell culture. Curr. Biol. 12, 1169-1177 (2002).
58. Svarovskaia, E. S. et al. Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions. J. Virol. 78, 3210-3222 (2004).
59. Bonnenfant, S. et al. Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents. J. Virol. 78, 5728-5736 (2004).
60. Hazuda, D. J. et al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl Acad. Sci. USA 101, 11233-11238 (2004).
61. King, P. J. & Robinson, W. E. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J. Virol. 72, 8420-8424 (1998).
62. Fikkert, V. et al. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J. Virol. 77, 11459-11470 (2003).
63. Mekouar, K. et al. Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. J. Med. Chem. 41, 2846-2857 (1998).
64. Deprez, E. et al.. Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro. Mol. Pharmacol. 65, 85-98 (2004).
65. Mousnier, A., Leh, H., Mouscadet, J. F. & Dargemont, C. Nuclear import of HIV-1 integrase is inhibited in vitro by styrylquinoline derivatives. Mol. Pharmacol. 66, 783-8 (2004).
66. Zouhiri, F. et al. Structure-Activity Relationships and Binding Mode of Styrylquinolines as Potent inhibitors of HIV-1 Integrase and Replication of HIV-1 in Cell Culture. J. Med. Chem. 43, 1533-1540 (2000).
67. Hong, H. et al. Discovery of human immunodeficiency virus type 1 integrase inhibitors by pharmacophore searching. J. Med. Chem. 40, 930-936 (1997).
68. Neamati, N. et al. Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. J. Med. Chem. 40, 942-951 (1997).
69. Fesen, M. R. et al. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem. Pharmacol. 48, 595-608 (1994).
70. Mazumder, A. et al. Inhibition of human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry 43, 13762-13771 (1996).
71. Cherepanov, P. et al. Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1. Mol. Pharmacol. 52, 771-780 (1997).
72. Pluymers, W. et al. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol. Pharmacol. 38, 641-648 (2000).
73. Mazumder, A. et al. Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease. J. Med. Chem. 39, 2472-2481 (1996).
74. Neamati, N. et al. Thiazolothiazepine inhibitors of HIV-1 integrase. J. Med Chem. 42, 3334-3341 (1999).
75. Rowley, D. C. et al. Thalassiolins A-C: new marine-derived inhibitors of HIV cDNA integrase. Bioorg. Med. Chem. 10, 3619-3625 (2002).
76. Neamati, N. et al. Metal-dependent inhibition of HIV-1 integrase. J. Med. Chem. 45, 5661-5670 (2002).
77. Neamati, N. et al. Highly potent synthetic polyamides, bisdistamycins, and lexitropsins as inhibitors of human immunodeficiency virus type 1 integrase. Mol. Pharmacol. 54, 280-290 (1998).
78. Farnet, C. M. et al. Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism. Antimicrob. Agents Chemother. 42, 2245-2253 (1998).
79. Mazumder, A., Raghavan, K., Weinstein, J., Kohn, K. W. & Pommier, Y. Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochem. Pharmacol. 49, 1165-1170 (1995).
80. Krajewski, K., Marchand, C., Long, Y. Q., Pommier, Y. & Roller, P. P. Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin. Bioorg. Med. Chem. Lett 14, 5595-5598 (2004).
81. Neamati, N. et al. Depside and depsidones as inhibitors of HIV-1 integrase: Discovery of novel inhibitors through 3D database searching. J. Med. Chem. 40, 942-951 (1997).
82. Goldgur, Y. et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc. Natl Acad. Sci. USA 96, 13040-13043 (1999).
83. Lubkowski, J. et al. Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor. Proc. Natl Acad. Sci. USA 95, 4831-4836 (1998).
84. Espeseth, A. S. et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. USA 97, 11244-11249 (2000).
85. Zhuang, L. et al. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J. Med. Chem. 46, 453-456 (2003).
86. Billich, A. S-1360 Shionogi-GlaxoSmithKline. Curr Opin Investig Drugs 4, 206-209 (2003).
87. Marchand, C. et al. Structural determinants for HIV-1 integrase inhibition by β-diketo acids. J. Biol. Chem. 277, 12596-12603 (2002).
88. Pais, G. C. et al. Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. J. Med. Chem. 45, 3184-3194 (2002).
89. Zhang, X. et al. Azido-containing aryl β-diketo acid HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett. 13, 1215-1219 (2003).
90. Zhang, X., Marchand, C., Pommier, Y. & Burke, T. R., Jr. Design and synthesis of photoactivatable aryl diketo acid-containing HIV-1 integrase inhibitors as potential affinity probes. Bioorg. Med. Chem. Lett. 14, 1205-1207 (2004).
91. Johnson, A. A. et al. Interaction between HIV-1 integrase Q148 and a viral DNA cytosine is required for strand transfer. (in the press).
92. Pommier, Y. & Cherfils, J. Interfacial inhibition of protein interactions: a Nature's paradigm for drug discovery. Trends Pharmacol. Sci. (in the press).
93. Tan, W., Zhu, K., Segal, D. J., Barbas, C. F., 3rd & Chow, S. A. Fusion proteins consistng of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc finger protein E2C direct integration of viral DNA into specific sites. J. Virol. 78, 1301-1313 (2004).
94. Bushman, F. D. & Miller, M. D. Tethering human immunodeficiency virus type 1 preintegration complexes to target DNA promotes integration at nearby sites. J. Virol. 71, 458-764 (1997).
95. Marques, M. A., Doss, R. M., Foister, S. & Dervan, P. B. Expanding the repertoire of heterocycle ring pairs for programmable minor groove DNA recognition. J. Am. Chem. Soc. 126, 10339-10349 (2004).
96. Bushman, F. D. & Craigie, R. Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. Proc. Natl Acad. Sci. USA 88, 1339-1343 (1991).
97. Hazuda, D. J., FelocK, P. J., Hastings, J. C., Pramanik, B. & Wolfe, A. L. Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase. J. Virol. 71, 7005-7011 (1997).
98. Farnet, C. M., Wang, B., Lipford, J. R. & Bushman, F. D. Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules. Proc. Natl Acad. Sci. USA 93, 9742-9747 (1996).
99. Hansen, M.S. et al. Integration complexes derived from HIV vectors for rapid assays in vitro. Nature Biotechnol. 17, 578-582 (1999).